Dashboard
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -15.26% and Operating profit at 0% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at 0 times
Flat results in Sep 26
Stock is technically in a Mildly Bearish range
Risky - Negative Book Value
Below par performance in long term as well as near term
Stock DNA
Trading & Distributors
INR 14 Cr (Micro Cap)
NA (Loss Making)
40
0.00%
-1.36
0.06%
-0.89
Total Returns (Price + Dividend) 
Norris Medicines for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Norris Medicines Ltd Downgraded to Strong Sell Amid Technical and Fundamental Weaknesses
Norris Medicines Ltd, a micro-cap player in the Trading & Distributors sector, has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 26 Oct 2026. This revision reflects deteriorating technical indicators, weak financial trends, poor valuation metrics, and declining quality scores, signalling heightened risk for investors amid a challenging market environment.
Read More
Broad-Based Technical Strength Lifts Norris Medicines Ltd to 52-Week High of Rs 20.06
With a fresh 52-week high of Rs 20.06 reached on 25 Sep 2026, Norris Medicines Ltd has demonstrated notable price momentum, outperforming the broader market which remains subdued near its own lows.
Read More
Broad-Based Technical Strength Lifts Norris Medicines Ltd to 52-Week High of Rs 19.71
Surging to a new 52-week high of Rs 19.71 on 22 Sep 2026, Norris Medicines Ltd has demonstrated remarkable price momentum, outperforming its sector by 4.94% today and extending a seven-day winning streak that has delivered a 35.93% return. This rally stands out amid a broader market environment where the Sensex remains subdued, trading near its 52-week low and below key moving averages.
Read More Announcements 
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Saturday November 14 2026
14-Nov-2026 | Source : BSEOutcome Of Board Meeting Held Today I.E. Saturday November 14 2026
Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September 2026
14-Nov-2026 | Source : BSEUn-audited financial results for the quarter and half year ended 30th September 2026
Board Meeting Intimation for Holding Board Meeting For Approval Of Un-Audited Financial Results For The Quarter And Half Year Ended September 30Th 2026 And Other Matters.
06-Nov-2026 | Source : BSENorris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 inter alia to consider and approve Un-Audited Financial Results For the Quarter and half year ended September 30th 2026 And Other Matters.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 2 Schemes (0.01%)
Held by 0 FIIs
Vimal D Shah (23.6%)
Fab Metals Private Limited (41.99%)
20.78%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is -28.26% vs -34.75% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 10.00% vs -900.00% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 73.87% vs -43.14% in Sep 2024
Growth in half year ended Sep 2025 is -41.10% vs 33.03% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 117.10% vs -25.30% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 67.33% vs 25.74% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 39.69% vs 3.19% in Mar 2025
YoY Growth in year ended Mar 2026 is 77.42% vs -4.20% in Mar 2025